Program
pegcetacoplan
Also written as “Pegcetacoplan”, “APL-2” and “PEGCETACOPLAN (APL-2)”.
Its studies are mostly in Geographic Atrophy · Hemoglobinuria, Paroxysmal · Glomerulonephritis, Membranoproliferative · Anemia, Hemolytic, Autoimmune · Macular Degeneration, led by 4 companies.
Drug pagePegcetacoplan: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biogenits history only | 244 open or running | phase 3since Apr 10, 2018 | Oct 8, 2014 | Jun 25, 2027phase 2 · NCT07215390 |
| Swedish Orphan Biovitrumits history only | 42 open or running | phase 4since Mar 26, 2026 | Oct 15, 2021 | Jan 17, 2031phase 3 · NCT07898774 |
| AbbVie | 11 open or running | phase 2since Aug 12, 2025 | Aug 12, 2025 | Oct 2029phase 2 · NCT07160179 |
| Hoffmann-La Rocheits history only | 10 open or running | phase 1since Apr 29, 2025 | Apr 29, 2025 | none ahead |
Also a collaborator on its studies: IQVIA Pty.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AbbVie only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2017Named pegcetacoplanINNProposed as its International Nonproprietary Name in WHO's List 118
- Aug 12, 2025First study: phase 2 study in Geographic AtrophyFirst studyNCT07160179 · 66 planned · United States
Ahead
- Oct 2029Primary completion: phase 2 study in Geographic AtrophyNCT07160179
TargetBeta
“A pegylated peptide inhibitor of human complement components C3 and C3b, ”NCIt, by rule
“Complement C3 inhibitor”ChEMBL 37, by rule
Other programs on C3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| SSS55rule | 3SBio | phase 1 | 1 |
Studies
The one study AbbVie leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07160179Geographic Atrophy · United States | 2 | Recruiting | Oct 2029 | 66 |
How it is read
Names in the registry
- “Pegcetacoplan”, 17 entries
- “APL-2”, 7 entries
- “PEGCETACOPLAN (APL-2)”, 2 entries
- “APL-3007, pegcetacoplan (APL-2)”, 2 entries
- “Syfovre™”, 1 entry
Conditions, from the studies’ own filings
- Geographic Atrophy, 9 studies
- Hemoglobinuria, Paroxysmal, 6 studies
- Glomerulonephritis, Membranoproliferative, 4 studies
- Anemia, Hemolytic, Autoimmune, 2 studies
- Macular Degeneration, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.